Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Ex-U.S. biotech executive fined for lying to auditors, charges dropped against CFO: SEC

Published 10/17/2019, 06:01 PM
Updated 10/17/2019, 06:04 PM
Ex-U.S. biotech executive fined for lying to auditors, charges dropped against CFO: SEC

Ex-U.S. biotech executive fined for lying to auditors, charges dropped against CFO: SEC

NEW YORK (Reuters) - The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a $40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday.

The SEC had alleged that Bobby Dwayne Montgomery prompted Osiris to book fake revenue and give false information to auditors. Montgomery agreed to a judgment that enjoins him from future violations of securities law, the SEC said in a statement.

"Our client is pleased to have resolved this matter on a no-admit no-deny basis, and looks forward to moving on with his life," said Stephen Crimmins, Montgomery's lawyer.

The biotech firm previously paid a $1.5 million penalty to settle charges of overstating company performance and issuing fraudulent financial statements for nearly two years, the regulator said.

The SEC said it last month dismissed charges against one of Osiris's former chief financial officers, Gregory I. Law. Litigation against two other executives is ongoing, the agency said.

"The SEC deserves credit for belatedly recognizing that Greg is innocent, but it doesn’t change the fact that he shouldn’t have been charged to begin with," said Aitan Goelman, counsel for Law.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.